Added to YB: 2026-04-09
Pitch date: 2026-02-13
LPCN [bullish]
Lipocine Inc.
-75.4%
current return
Author Info
No bio for this author
Company Info
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology.
Market Cap
$14.2M
Pitch Price
$8.66
Price Target
60.00 (+2717%)
Dividend
N/A
EV/EBITDA
0.03
P/E
-1.10
EV/Sales
-0.16
Sector
Pharmaceuticals
Category
growth
Lipocine Inc. - $LPCN
LPCN: Oral brexanolone (LPCN1154) Ph3 readout early Q2 for PPD. PK-equivalent to approved IV brex, proven efficacy in HAM-D>25 pts. Zurzuvae comp doing $200M sales (+100% YoY) validates mkt; SAGE acquired for $400M+ pre-mkt proof. Best-in-class: 2-day course vs 14-day Zur (black box sedation). Trial powered at 70% PoS. $47M mcap vs est $40-60 target on success = 300-500% upside. Risks: small biotech execution, placebo response, FDA REMS, need partnership, -80% downside if fail.
Read full article (10 min)